Tumor necrosis factor antagonists and their use
AssigneeGenentech, Inc.
InventorsBharat B. Aggarwal, Michael A. Palladino, Mohamed R. Shalaby
Life of this patent
Estimating the term…
Abstract
Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis factor. The antagonists are useful in suppressing transplantation immunity and in the treatment of autoimmune diseases.
Claims15
A tumor necrosis factor-alpha (TNF-alpha) antagonist comprising an antibody which neutralizes cytotoxic activity of human TNF-alpha.
A TNF-alpha antagonist comprising an anti-TNF-alpha antibody which blocks cytotoxic activity of human TNF-alpha.
A TNF-alpha antagonist comprising a monoclonal antibody which neutralizes cytotoxic activity of human TNF-alpha, wherein said antibody is generated using a human TNF-alpha protein which, when in a purified form, migrates as a single band on a SDS-PAGE gel to a molecular weight of about 17,000 daltons.
A TNF-alpha antagonist consisting of a monoclonal anti-TNF-alpha antibody which blocks cytotoxic activity of TNF-alpha on murine L-929 cells in vitro.
Dependencies are inferred from the claim text.